VSTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Verastem, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.62−0.03 (-0.35%)
Close on Oct 19, 2026
- Market cap
- $863.00M
- P/E (TTM)
- –
- Dividend yield
- –
Verastem statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Verastem | Industry median |
|---|---|---|
| Market Cap | $780.66M | $197.05M |
| Enterprise Value | $644.26M | $106.56M |
| PS Ratio | 8.92 | 3.93 |
| PB Ratio | 15.62 | 2.14 |
| P/TBV Ratio | 22.88 | 2.46 |
Enterprise value
| Measure | Verastem | Industry median |
|---|---|---|
| EV / Sales | 7.36 | 2.69 |
Income (trailing twelve months)
| Measure | Verastem | Industry median |
|---|---|---|
| Revenue | $87.53M | $57.94M |
| Operating Income | -$159.80M | -$21.44M |
| Net Income | -$202.70M | -$22.46M |
| EBITDA | -$159.80M | -$16.91M |
| EPS (Diluted) | -$2.55 | -$0.83 |
Margins
| Measure | Verastem | Industry median |
|---|---|---|
| Operating Margin | -182.6% | -44.5% |
| Profit Margin | -231.6% | -39.2% |
| EBITDA Margin | -182.6% | -31.3% |
Returns
| Measure | Verastem | Industry median |
|---|---|---|
| Return on Equity (ROE) | -471.2% | -53.1% |
| Return on Assets (ROA) | -100.7% | -41.0% |
| Return on Capital Employed (ROCE) | -124.5% | -37.8% |
Growth
| Measure | Verastem | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | 128.4% | 2.25% |
| Revenue Growth (5Y CAGR) | -19.0% | 6.42% |
Balance sheet
| Measure | Verastem | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $136.40M | $62.42M |
| Net Cash (Debt) | $136.40M | $15.68M |
| Net Cash Per Share | $1.51 | $0.65 |
| Equity (Book Value) | $49.99M | $48.79M |
| Book Value Per Share | $0.55 | $1.36 |
| Tangible Book Value | $34.12M | $23.06M |
| Working Capital | $98.03M | $75.77M |
Financial position
| Measure | Verastem | Industry median |
|---|---|---|
| Current Ratio | 2.25 | 3.30 |
| Quick Ratio | 2.12 | 2.39 |
| Interest Coverage | -108.26 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Verastem | Industry median |
|---|---|---|
| Operating Cash Flow | -$162.20M | -$12.35M |
Efficiency
| Measure | Verastem | Industry median |
|---|---|---|
| Asset Turnover | 0.43 | 0.38 |
| Revenue Per Employee | $858.10K | $398.96K |
| Profits Per Employee | -$1.99M | -$732.08K |
| Employee Count | 102 | 73 |
Dividends and yields
| Measure | Verastem | Industry median |
|---|---|---|
| Earnings Yield | -26.0% | -21.2% |
Shares
| Measure | Verastem | Industry median |
|---|---|---|
| Shares Outstanding | 90,563,400 | 59,128,900 |
| Shares Change (QoQ) | 3.00% | 0.54% |
| Float | 89,007,200 | 48,744,500 |
| Shares Held by Insiders | 1.72% | 11.8% |
| Shares Held by Institutions | 109.2% | 59.4% |
Scores
| Measure | Verastem | Industry median |
|---|---|---|
| Altman Z-Score | -6.95 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Verastem's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.